Recon Strategy
Contact

Insights

Fifteen+ years of
healthcare thinking.

Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.

ESSENTIAL READING

  • Biopharma, Payers, Institutional

Outcomes Based Arrangements in Biopharma

Today’s advanced therapies target devastating diseases with high unmet need. Given the urgent medical need (and pressure from patient advocates), regulators increasingly must make decisions based on early, incomplete data when it comes to durability, real-world effectiveness, and cost-effectiveness – all while bearing costs that can exceed $1 million per patient.
  • Biopharma

A few thoughts about navigating biopharma macro scenarios

Planning biopharma strategies against a robust set of macro-scenarios will be crucial to mid- and long-term success. While historically these scenarios have revolved around targeted issues, the current challengescall for a more expansive - and likely more difficult - set of questions to be asked.
  • Biopharma, Payers, Providers, Medtech, Digital

Why the Best AI Won’t Win in Healthcare

As advanced AI becomes widely accessible, healthcare companies can no longer rely on superior technology alone for lasting advantage. Instead, they need a coherent AI strategy built around five interconnected choices. Harvard Business Review article.
Sector
All
NEJM opinion

Eating your way out of disease: An opinionated take on NEJM highlights for November 2018

  • NEJM
Peanut medicine that won’t cost peanuts Allergy to peanuts is a major …

Read more

New class of therapeutics calls for new regulations: thoughts on the FDA’s new process for regulating digiceuticals

  • Medtech , 
  • Digital
Interest and investment in digital health has increased rapidly in rec…

Read more

T-cells are everywhere: An opinionated take on NEJM highlights for October 2018

  • NEJM
One century after the use of convalescent serum, convalescent T-cells …

Read more

An opinionated take on NEJM highlights for September 2018

  • NEJM
Primary care organizations are better ACOs when it comes to achieving …

Read more

An opinionated take on NEJM highlights for August 2018

  • NEJM
Transthyretin heats up Last month saw a couple landmark papers about t…

Read more

What’s harder, making new drugs or improving care delivery at scale? An opinionated take on NEJM highlights for July 2018

  • NEJM
RNA drugs coming of age Hereditary Transthyretin Amyloidosis (ATTR) is…

Read more

An opinionated take on NEJM highlights for June 2018

  • NEJM
It’s hard to quit (and E-cigs don’t help) A large trial (6000 particip…

Read more

Struggling: An opinionated take on NEJM highlights for May 2018

  • NEJM
One more on the chin for Alzheimer’s A report of a large phase 3 study…

Read more

An opinionated take on NEJM highlights for April 2018

  • NEJM
Are we nearing an asymptote with implantable cardiac pumps? Severe hea…

Read more

SELECTED ENGAGEMENTS

Insight, put to work

Our published thinking is one half of the picture. These are representative client engagements, anonymized — each tagged by sector, so you can trace the path from perspective to practice.

  • Institutional

Strategy for Statewide Health Information Exchange

A non-profit health information exchange was facing financial struggles and needed a new strategy that would keep it financially sustainable

HIE, Health IT,

  • Medtech, Early Stage

Growth strategy for point-of-care testing

Post pandemic an innovative diagnostics platform company wanted to dramatically increase its market by targeting retail clinics for its point-of-care diagnostics platform

Growth, product market fit, value proposition

  • Institutional

University Trials

Large university wanting to dramatically increase its clinical research footprint

Keep up with Recon Strategy Insights
Get an email each time we publish a new article